{"id":2804,"date":"2021-01-01T12:05:00","date_gmt":"2021-01-01T11:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2021\/leserbrief-antithrombotische-tripeltherapie"},"modified":"2021-01-01T12:05:00","modified_gmt":"2021-01-01T11:05:00","slug":"leserbrief-antithrombotische-tripeltherapie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2021\/leserbrief-antithrombotische-tripeltherapie","title":{"rendered":"Leserbrief: Antithrombotische Tripeltherapie"},"content":{"rendered":"<p>Dres. G.E. und H.W. aus Bremen schreiben (stark gek\u00fcrzt): >> In Ihrem Artikel zur antithrombotischen Tripeltherapie nach akutem Koronarsyndrom bei Patienten mit oraler Dauerantikoagulation (1) wird suggeriert, die generelle Bevorzugung direkter oraler Antikoagulanzien (DOAK) vor Vitamin-K-Antagonisten (VKA) bei Vorhofflimmern (VHF) sei leitliniengerecht. Das mag f\u00fcr die ESC-Leitlinie gelten, allerdings haben die Akd\u00c4 und die DEGAM [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dres. G.E. und H.W. aus Bremen schreiben (stark gek\u00fcrzt): >> In Ihrem Artikel zur antithrombotischen Tripeltherapie nach akutem Koronarsyndrom bei Patienten mit oraler Dauerantikoagulation (1) wird suggeriert, die generelle Bevorzugung direkter oraler Antikoagulanzien (DOAK) vor Vitamin-K-Antagonisten (VKA) bei Vorhofflimmern (VHF) sei leitliniengerecht. Das mag f\u00fcr die ESC-Leitlinie gelten, allerdings haben die Akd\u00c4 und die DEGAM [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[185,74,684,495,137,1322,60,1272,77,5312,76,73,1314,1312,2068,5311,71,68,498,65,1328,1327,138,1033,56,727,2005,4833,181,136],"class_list":["post-2804","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-acetylsalicylsaeure","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-antikoagulanzien","tag-apixaban","tag-apoplektischer-insult","tag-arteriosklerose","tag-ass","tag-augustus-studie","tag-azetylsalizylsaeure","tag-clopidogrel","tag-direkte-orale-antikoagulanzien","tag-doak","tag-edoxaban","tag-entrust-af-studie","tag-herzinfarkt","tag-hirninfarkt","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-neue-orale-antikoagulanzien","tag-noak","tag-phenprocoumon","tag-prasugrel","tag-schlaganfall","tag-thrombozytenaggregationshemmer","tag-ticagrelor","tag-tripel-therapie","tag-vorhofflimmern","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2804"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2804\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}